title: Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolérance: in vitro and in vivo considerations.
abstract: OBJECTIVE
  Probiotics are live microorganisms which when administered in adequate amounts confer a health benefit on the host. In inflammatory bowel disease (IBD), where major modifications of the intestinal microflora have been reported, there is an increasing interest in modulating the flora with probiotic products. This work addresses the anti-inflammatory potential of Lactibiane Tolérance, a probiotic dietary supplement (mixture of four strains) using in vitro and in vivo approaches.
  
  
  METHODS
  Comparison of the four individual strains and the commercial product reconstituted from them was conducted by in vitro tests (cytokine release after 24h stimulation of human peripheral blood mononuclear cells (PBMC)). The potential immunomodulatory characteristics of Lactibiane Tolérance were determined in vivo in an acute mice model of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. Assessment of colitis included blinded histological and macroscopic scores.
  
  
  RESULTS
  We showed that Lactibiane Tolérance has anti-inflammatory properties in vitro by stimulating IL-10 production and in vivo by conferring a significant protective effect in the TNBS-induced colitis model (more than 50% decrease of colitis symptoms, P<0.01).
  
  
  CONCLUSIONS
  These results demonstrate that a probiotic dietary supplement, Lactibiane Tolérance, can significantly prevent the initial injury of TNBS and could stimulate the initiation of clinical trials in IBD.
authors.affiliation: PiLeJe, 37 Quai de Grenella, 75738 Paris Cedex 15, France. s.holowacz@pileje.com
authors.forename: Sophie
authors.initials: S
authors.lastname: Drouault-Holowacz
authors.forename: Benoît
authors.initials: B
authors.lastname: Foligné
authors.forename: Véronique
authors.initials: V
authors.lastname: Dennin
authors.forename: Denise
authors.initials: D
authors.lastname: Goudercourt
authors.forename: Kathleen
authors.initials: K
authors.lastname: Terpend
authors.forename: André
authors.initials: A
authors.lastname: Burckel
authors.forename: Bruno
authors.initials: B
authors.lastname: Pot
mesh_terms: D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001644:Bifidobacterium / Q000254:growth & development / Q000502:physiology; D002478:Cells, Cultured; D003092:Colitis / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control / Q000628:therapy; D016207:Cytokines / Q000096:biosynthesis; D019587:Dietary Supplements; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000382:microbiology / Q000473:pathology / Q000517:prevention & control / Q000628:therapy*; D007778:Lactobacillus / Q000254:growth & development / Q000502:physiology; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D019936:Probiotics; D011897:Random Allocation; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014302:Trinitrobenzenesulfonic Acid / Q000633:toxicity
chemical_list: D000893:Anti-Inflammatory Agents; D016207:Cytokines; D014302:Trinitrobenzenesulfonic Acid